The HCT/P Modernization Act of 2025
- Bill Number
- H.R. 340
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-01-13: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2025-03-21T16:30:20Z
AI-Generated Summary
Purpose of the Legislation
The HCT/P Modernization Act of 2025 aims to streamline the regulatory oversight of human cell and tissue products (HCT/Ps) by the Food and Drug Administration (FDA). These products include items like stem cells or tissues used in medical treatments. The goal is to improve transparency, education, and efficiency in FDA's processes, while supporting scientific progress and public health protection without overhauling core regulations.
Key Provisions
- Information and Transparency Requirements:
- The FDA must create a public website section with educational materials about the Tissue Reference Group (an FDA advisory body for HCT/P questions) and best practices for getting quick, accurate advice from it.
- Starting one year after enactment, the FDA must annually publish data for four years on:
- Number of HCT/P establishments registered since January 1, 2019.
- Number of FDA inspections of these establishments since that date, compared to blood establishment inspections.
- Number and types of inquiries to the Tissue Reference Group.
- Average response times for these inquiries (initial and final).
- The FDA must educate stakeholders (e.g., industry, tissue banks, researchers, patients) through information sharing and workshops to promote predictable regulations and scientific advances.
- Updates to Scientific Guidance:
- Amends a section of the 2022 Food and Drug Omnibus Reform Act to expand FDA guidance on best practices for generating scientific data on stem cell and other cellular therapies, including the latest scientific information.
- Public Engagement:
- Within 60 days of enactment, the Secretary of Health and Human Services (HHS) must open a public docket for comments on modernizing HCT/P regulations, focusing on workshop topics and concepts like "minimal manipulation" (keeping the product close to its natural state) and "homologous use" (using the product for its intended natural function).
- Congressional Reporting:
- By September 30, 2026, HHS must submit a report to Congress summarizing public workshop and docket discussions, with recommendations on HCT/P regulations. This includes reviewing rules on establishment registration and product definitions, while balancing regulatory burden, scientific advances, access to these products under section 361 of the Public Health Service Act (which covers preventive health measures), and public health safeguards.
Significant Changes to Existing Law
- Minor Amendment to 2022 Law: Updates language in the Food and Drug Omnibus Reform Act to broaden guidance from "best practices" for certain therapies to include comprehensive scientific data generation and updates on stem cell and cellular products. This enhances but does not fundamentally alter prior requirements.
- No broad repeal or rewrite of existing FDA regulations on HCT/Ps (e.g., under 21 CFR Part 1271), but it introduces new transparency, reporting, and engagement mandates to modernize implementation.
Potential Impacts
- On Government Agencies: Increases administrative workload for FDA and HHS through website updates, data publication, education efforts, public dockets, and a congressional report. This could improve internal efficiency in handling HCT/P inquiries but requires resource allocation.
- On Citizens and Patients: Enhances access to clear information on HCT/P regulations, potentially speeding up approvals or advice for therapies like regenerative medicine. May indirectly improve patient safety and treatment options by fostering innovation, though direct access changes depend on future recommendations.
- On International Relations: Minimal direct impact, as the bill focuses on domestic FDA processes; however, clearer U.S. regulations could influence global standards for HCT/P exports/imports by aligning with international scientific norms.
Main Stakeholders Affected
- FDA and HHS: Primary implementers, responsible for new transparency and reporting duties.
- Tissue Establishments and Industry: Benefit from better guidance, faster responses, and reduced uncertainty in registering products or seeking advice.
- Researchers, Academic Health Centers, and Biomedical Groups: Gain from educational workshops and scientific updates to support innovation.
- Patients and Advocacy Groups: Receive more public information, potentially leading to safer, more accessible cellular therapies.
- Congress: Receives a report to inform future oversight or legislation on HCT/Ps.
Notable Legal, Constitutional, or Political Implications
- Legal: Reinforces existing FDA authority under the Public Health Service Act without expanding or challenging it, emphasizing administrative streamlining. The public docket and report promote stakeholder input, aligning with Administrative Procedure Act requirements for transparent rulemaking.
- Constitutional: No apparent issues; the bill supports Congress's enumerated power to regulate interstate commerce and public health without infringing on individual rights.
- Political: Bipartisan introduction (by Rep. Crenshaw and Rep. Barragán) signals broad support for balancing innovation with safety in emerging biotech fields. It could set a precedent for iterative regulatory modernization in health tech, potentially reducing industry burdens amid debates over overregulation, but outcomes hinge on the 2026 report's recommendations.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Rep. Barragán, Nanette Diaz [D-CA-44]
Recent Actions
- 2025-01-13: Referred to the House Committee on Energy and Commerce.
- 2025-01-13: Introduced in House
- 2025-01-13: Introduced in House
Bill Versions
- The HCT/P Modernization Act of 2025 — issued 2025-01-13 — PDF (6 pages)